Abstract Search

hrp0098p2-351 | Late Breaking | ESPE2024

Up to 5 years of once-weekly somatrogon treatment in pediatric patients with growth hormone deficiency: results from an open-label extension of a global Phase 3 study

Silverman Lawrence , Steelman Joel , Choe John , Stawerska Renata , Deal Cheri , Wajnrajch Michael , Thomas Marc , La Torre Daria , Phillip Moshe , Taylor Carrie , Wang Rong , Cara Jose

Objective: Somatrogon, a long-acting recombinant human growth hormone (rhGH) is approved as a once-weekly treatment for pediatric growth hormone deficiency (pGHD). This abstract describes the long-term efficacy and safety of somatrogon in patients with pGHD following up to 5 years of treatment in a global, Phase 3 study (NCT02968004).Methods: In the main study period, patients were randomized to receive either once-weekl...

1 shares

ESPE Abstracts

Up to 5 years of once-weekly somatrogon treatment in pediatric patients with growth hormone deficiency: results from an open-label extension of a global Phase 3 study

BiosciAbstracts